SCHEMBL23110348

SCHEMBL23110348

N#Cc1cc(N2CCC(NCCO)CC2)nc2ccc(Cl)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 4/20 0.44
HTR3A P46098 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
P2RX7 Q99572 1/20 0.41
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
EGFR P00533 2/20 0.38
CYP3A4 P08684 1/20 0.37
DPP4 P27487 1/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23110351 0.86 L3MBTL1 (0.58) HRH4HTR3AL3MBTL1HTTATM
SCHEMBL23110345 0.84 RAB9A (0.58) HRH4HTR3AMEN1NPC1RAB9A
SCHEMBL23110068 0.82 HTT (0.48) HRH4HTR3AL3MBTL1HTTATM
SCHEMBL23110346 0.81 HRH4 (0.46) HRH4HTR3AP2RX7MEN1NPC1
SCHEMBL23110349 0.80 HTR3A (0.51) HRH4HTR3AL3MBTL1HTTATM
SCHEMBL23110347 0.79 HRH3 (0.57) HRH4HTR3AP2RX7MCHR1HRH3
SCHEMBL23110353 0.79 L3MBTL1 (0.53) HRH4HTR3AL3MBTL1HTTATM
SCHEMBL23110431 0.78 AR (0.50) HTR3AL3MBTL1HTTATMP2RX7
SCHEMBL23110447 0.78 AR (0.50) HTR3AL3MBTL1HTTATMP2RX7
SCHEMBL23110352 0.78 L3MBTL1 (0.52) L3MBTL1HTTATMMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315568-A1 INHIBITORS OF SARM1 DISARM THERAPEUTICS, INC. 2022-10-06 US disclosed
WO-2021050913-A1 INHIBITORS OF SARM1 DISARM THERAPEUTICS, INC. (US) 2021-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315568-A1 INHIBITORS OF SARM1 SARM1, SMN1; SMN2, SARNP HRH4 4644/4885HTR3A 3781/4885L3MBTL1 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.